Abstract：
TFIIIB is deregulated in a variety of cancers. However, few studies investigate the TFIIIB subunit BDP1 in cancer. BDP1 has not been studied in breast cancer patients. Herein, we analyzed clinical breast cancer datasets to determine if BDP1 alterations correlate with clinical outcomes. BDP1 copy number (n = 1602; p = 8.03 × 10-9) and mRNA expression (n = 130; p = 0.002) are specifically decreased in patients with invasive ductal carcinoma (IDC). In IDC, BDP1 copy number negatively correlates with high grade (n = 1992; p = 2.62 × 10-19) and advanced stage (n = 1992; p = 0.005). BDP1 mRNA expression also negatively correlated with high grade (n = 55; p = 6.81 × 10-4) and advanced stage (n = 593; p = 4.66 × 10-4) IDC. Decreased BDP1 expression correlated with poor clinical outcomes (n = 295 samples): a metastatic event at three years (p = 7.79 × 10-7) and cancer reoccurrence at three years (p = 4.81 × 10-7) in IDC. Decreased BDP1 mRNA correlates with patient death at three (p = 9.90 × 10-6) and five (p = 1.02 × 10-6) years. Both BDP1 copy number (n = 3785; p = 1.0 × 10-14) and mRNA expression (n = 2434; p = 5.23 × 10-6) are altered in triple-negative invasive breast cancer (TNBC). Together, these data suggest a role for BDP1 as potential biomarker in breast cancer and additional studies are warranted.
摘要：
TFIIIB在多种癌症中失调。然而,很少有研究探讨TFIIIB亚基BDP1在癌症中的作用。BDP1尚未在乳腺癌患者中进行研究。在这里，我们分析了临床乳腺癌数据集,以确定BDP1改变是否与临床结局相关.在浸润性导管癌（IDC）患者中，BDP1拷贝数（n=1602；p=8.03×10-9）和mRNA表达（n=130；p=0.002）特异性降低。在IDC中,BDP1拷贝数与高级（n=1992；p=2.62×10-19）和高级（n=1992；p=0.005）呈负相关。BDP1mRNA表达也与高级别（n=55；p=6.81×10-4）和晚期（n=593；p=4.66×10-4）IDC呈负相关。BDP1表达降低与不良临床结果相关（n=295个样本）：IDC中三年转移事件（p=7.79×10-7）和三年癌症复发（p=4.81×10-7）。BDP1mRNA降低与患者3年（p=9.90×10-6）和5年（p=1.02×10-6）死亡相关。在三阴性浸润性乳腺癌（TNBC）中，BDP1拷贝数（n=3785；p=1.0×10-14）和mRNA表达（n=2434；p=5.23×10-6）均发生改变。一起,这些数据提示BDP1在乳腺癌中作为潜在的生物标志物发挥作用,因此需要进一步的研究.
